PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 21, 2026ESMO Open2 citationsOpen Access

114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)

View Full Paper
GSG. SchvartsmanHospital Israelita Albert EinsteinDYD. YueTianjin Medical University Cancer Institute and HospitalMPM. Provencio PullaHospital Universitario Puerta de Hierro Majadahonda

Key Points

  • This research aims to explore the impact of residual viable tumor and nodal status on survival in resectable non-small cell lung cancer patients treated with tislelizumab.
  • Conducted a retrospective analysis of patients with resectable non-small cell lung cancer.
  • Assessed the correlation between residual viable tumor and nodal status with patient survival.
  • Evaluated the effects of perioperative tislelizumab treatment.
  • Patients with lower residual viable tumor had improved survival rates.
  • Nodal status was a significant predictor of patient outcomes.
  • T-cell functionality was associated with durable treatment benefits.

Abstract

m on Q6W combo (p<0.1;n=10), indicating better T-cell functionality in patients with durable benefit. Conclusions:These translational results indicate biological and clinical activity of acasunlimab + pembro in PD-L1+ mNSCLC, supporting a less frequent dosing paradigm (Q6W) to reinvigorate and maintain T-cell functionality post-CPI.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schvartsman et al. (2026) studied this question.

synapsesocial.com/papers/69be34d16e48c4981c672efchttps://doi.org/10.1016/j.esmoop.2026.106421
Ask AI
Helpful
Bookmark
Share
View Full Paper